# Metoprolol XR in Heart Failure With Normal Ejection Fraction

Study · id `cardio:ct-nct03882710` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03882710](<https://clinicaltrials.gov/study/NCT03882710>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03882710

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 102 participants.

## Technical summary

Registry record NCT03882710. Randomized; double masking; primary purpose treatment. Start 2010-01 (registry gives no type); primary completion 2012-10 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 102 participants (enrolled count; ClinicalTrials.gov record NCT03882710, source copy `cardio:ctgov-nct03882710-2019-03-21`, retrieved 2026-10-26)
- Start date: 2010-01 (registry gives no type) (ClinicalTrials.gov record NCT03882710, source copy `cardio:ctgov-nct03882710-2019-03-21`, retrieved 2026-10-26)
- Primary completion: 2012-10 (actual) (ClinicalTrials.gov record NCT03882710, source copy `cardio:ctgov-nct03882710-2019-03-21`, retrieved 2026-10-26)
- Completion: 2012-12 (actual) (ClinicalTrials.gov record NCT03882710, source copy `cardio:ctgov-nct03882710-2019-03-21`, retrieved 2026-10-26)
- Countries: India (ClinicalTrials.gov record NCT03882710, source copy `cardio:ctgov-nct03882710-2019-03-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03882710-2019-03-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: Metoprolol XR in Heart Failure With Normal Ejection Fraction
- Acronym: HFNEF
- Condition: Diastolic Heart Failure
- Intervention (Drug): Metoprolol XR
- Lead sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Heart failure with mildly reduced or preserved ejection fraction (`cardio:hfpef`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Metoprolol (`cardio:metoprolol`)
- Registry intervention is a member of this class by a sourced record link: Beta-blockers (drug class) (`cardio:beta-blockers`)
- Registry lists this organization as the lead sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh (`cardio:org-post-graduate-institute-of-medical-education-and-research-6933b6`)

## Provenance

Content hash: 412f59f2b6346db2ad9796cfc7752516c7c56a9eb17f409acbb0d26b9dc8f6a4
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
